0001654954-23-002981.txt : 20230413 0001654954-23-002981.hdr.sgml : 20230413 20230316111749 ACCESSION NUMBER: 0001654954-23-002981 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dermata Therapeutics, Inc. CENTRAL INDEX KEY: 0001853816 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 3525 DEL MAR HEIGHTS RD., #322 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858)-223-0882 MAIL ADDRESS: STREET 1: 3525 DEL MAR HEIGHTS RD., #322 CITY: SAN DIEGO STATE: CA ZIP: 92130 CORRESP 1 filename1.htm drma-besteffortss1acceler
 
March 16, 2023
 
VIA EDGAR
 
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
 
 Re:
Dermata Therapeutics, Inc. (the “Company”) 
 
Registration Statement on Form S-1 (File No. 333-270195)    
 
 
Ladies and Gentlemen:
 
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 3:00 p.m., Eastern Time, on March 16, 2023, or as soon as practicable thereafter.
 
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.
 
Very truly yours,
 
DERMATA THERAPEUTICS, Inc.
 
 
 

 
 
 
 
 

By:  
/s/  Gerald T. Proehl
 
 
 
Gerald T. Proehl
 
 
 
Chief Executive Officer